From ipowerbioinfo from gmail.com Sun May 17 23:33:30 2009 From: ipowerbioinfo from gmail.com (ipower) Date: Mon May 18 11:25:26 2009 Subject: [Cell-biology] Bioinformatics Summer training & Projects Message-ID: Greetings from iPower Solutions India Ltd, Chennai iPower Solutions India Ltd is a premier training institute in Chennai offering a Research and Industry oriented training in Bioinformatics. We are specializing in Course Training, Certificate Course, PGDBI, Project Guidance, and Summer Training in diverse application areas. Bioinformatics Course Training: Duration: 2 Weeks Introduction to Bioinformatics Bioinformatics tools and databases Proteomic tools and Databases Genomic tools and databases Introduction to genomics Introduction to Proteomics Introduction to Drug designing &Software=92s Inplant /Summer Projects Domains: Duration: 1 Month Comparative Genomics DNA Sequence analysis Drug Designing Docking Gene prediction Herbal Informatics Microbial Genomics Protein Sequence analysis Phylogenetic analysis. System biology Further information contact to us: iPower Solutions India Ltd, Bioinformatics Coordinator, Adambakkam, Chennai-600 088 Website: www.ipbioinformatics.com E-mail: project@ipwrs.com From scimedweb from mail.com Wed May 20 04:19:45 2009 From: scimedweb from mail.com (scimedweb@mail.com) Date: Wed May 20 11:00:22 2009 Subject: [Cell-biology] Molecular Therapy of Breast Cancer: Classicism Meets Modernity (announcing) Message-ID: Molecular Therapy of Breast Cancer: Classicism Meets Modernity (book). by Marc Lacroix InTextoResearch, Baelen (Li=E8ge, Wallonia), Belgium Nova Sciences Publishers, New York, ISBN 978-1-60741-593-0 https://www.novapublishers.com/catalog/product_info.php?cPath=3D23_29&produ= cts_id=3D10042&osCsid=3D8fed1efc6158a0ba4004bec047b66ff0 Breast cancer is the most frequently diagnosed type of cancer and a second leading cause of cancer death in women after lung cancer. Despite their proven efficacy, classical therapies are, however, unable to cure metastatic breast cancer and are often associated with significant toxicity and side-effects, due to a wide spectrum of action. During the last years, our increasing knowledge of the molecular pathways underlying cancer development has led to the introduction of new drugs, of which most are directed towards very specific targets. Rather than to be used as single agents, these =93modern=94 compounds could ultimately be combined with classical molecules. Here are described nearly 150 drugs that are currently used in routine therapy or are in clinical trials in breast cancer patients. From the classical tamoxifen, fluorouracil, cyclophosphamide, doxorubicin, epirubin, docetaxel, paclitaxel=85, to the more recently introduced ixabepilone, lapatinib, vorinostat, everolimus, bevacizumab=85, they also include capecitabine, gemcitabine, trastuzumab, bevacizumab, fulvestrant, aromatase inhibitors, cancer vaccines, inhibitors of tumor-induced osteolysis, insulin-like growth factor-I receptor inhibitors, poly(ADP-ribose) polymerase (PARP)-1 inhibitors, and many others. This book offers an insight into current developments of breast cancer therapy, when classicism meets modernity. Table of Contents: Chapter 1. Introduction Chapter 2. Selective estrogen receptor modulators (SERMs) and down- regulators (SERDs) Chapter 3. Aromatase inhibitors Chapter 4. Agents inducing ovarian suppression Chapter 5. Antimetabolites Chapter 6. Alkylating agents Chapter 7. Anthracyclines Chapter 8. Microtubule-binding agents Chapter 9. Topoisomerase inhibitors Chapter 10. HER family inhibitors Chapter 11. Angiogenesis inhibitors Chapter 12. Insulin-like growth factor-I receptor inhibitors Chapter 13. RAS-RAF-MEK-ERK pathway inhibitors Chapter 14. Ubiquitin-proteasome system inhibitors Chapter 15. Histone deacetylases inhibitors Chapter 16. Mitotic inhibitors Chapter 17. Inhibitors of heat-shock proteins 90 and 27 Chapter 18. PI3K/AKT/mTOR pathway inhibitors Chapter 19. Cyclooxygenase-2 inhibitors Chapter 20. Poly(ADP-ribose) polymerase (PARP)-1 inhibitors Chapter 21. Tumor-induced osteolysis inhibitors Chapter 22. Vaccines and immunomodulators Chapter 23. Varia Index List of drugs/compounds discussed in the book: ABT-888, ABT-869, Ad-sig-hMUC-1/ecdCD40L vaccine, AE37 peptide/GM-CSF vaccine, Aflibercept, AFP464, AG014699, Alendronate, Aldesleukin, Allogeneic GM-CSF-secreting breast cancer vaccine, ALT-801, AMG 386, AMG 479, Anastrozole, Apricoxib, ARRY-334543, AS1402, ATN-224, Autologous dendritic cell-adenovirus p53 vaccine, AV-951, AVE1642, AVX701, AZD0530, AZD6244, Bavituximab, Belinostat, Bevacizumab, BGT226, BIBW 2992, BMS-754807, Bortezomib, Bosutinib, BSI-201, Busulfan, BZL101, Capecitabine, Carboplatin, CDX-1307, Celecoxib, Cetuximab, CHP-HER2, CHP-NY-ESO-1, Cisplatin, Cixitumumab, Clodronate, CNF2024, CR011-vcMMAE, Cyclophosphamide, Dasatinib, Deforolimus, Denileukin diftitox, Denosumab, Docetaxel, Doxorubicin, Entinostat, Enzastaurin, Epirubicin, Eribulin , Erlotinib, Ertumaxomab, Etoposide, Everolimus, Exemestane, Falimarev, Figitumumab, Fluorouracil, Fulvestrant, Gefitinib, Gemcitabine, Goserelin, GP2 peptide/GM-CSF vaccine, GRN163L, GSK1059615, HER2/neu (extracellular domain) peptide vaccine, hTERT/Survivin Multi-Peptide Vaccine, Ibandronate, Ifosfamide, Imatinib, IMP321, Inalimarev, Interleukin-12, Irinotecan, Ispinesib, Ixabepilone, Lapatinib, Larotaxel, Letrozole, Leuprolide, Lonafarnib, Lonaprisan, Mammaglobin-A DNA vaccine, Melphalan, Methotrexate, MK0646, MK-0752, MLN8237, Modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine, Neratinib, NVP-AUY922, NVP-BEZ235, Odanacatib, OGX-427, Olaparib, OSI-906, Ovarian Cancer Peptide Mix Immunotherapeutic Vaccine, Oxaliplatin, Paclitaxel, Panobinostat, Patupilone, Pazopanib, PD-0332991, Pemetrexed, Pertuzumab,Picoplatin, pNGVL3-hICD vaccine, PTC299, Ramucirumab, Recombinant fowlpox-CEA(6D)/ TRICOM vaccine, Recombinant vaccinia-CEA(6D)-TRICOM vaccine, Retaspimycin, Rexin-G, Risedronate, Sagopilone, SCH 727965, Sialyl Lewis=AA-keyhole limpet hemocyanin (KLH) conjugate vaccine, Sirolimus, Sorafenib, Sunitinib, Tamoxifen, Telomerase: 540-548 peptide vaccine, Temozolomide, Temsirolimus, Tesmilifene, Thiotepa, Tipifarnib, Toremifene, Trabectedin, Trastuzumab, Trastuzumab-MCC-DM1, Triptorelin, TTK peptide (mixed with adjuvant Montanide ISA-51), Valproic Acid, Vandetanib, Vinflunine, Vinorelbine, Vorinostat, WX-671, Zoledronic Acid From bks from panix.com Wed May 20 09:12:33 2009 From: bks from panix.com (Bradley K. Sherman) Date: Wed May 20 11:00:25 2009 Subject: [Cell-biology] Re: Molecular Therapy of Breast Cancer: Classicism Meets Modernity (announcing) References: Message-ID: In article , wrote: >Molecular Therapy of Breast Cancer: Classicism Meets Modernity (book). >by Marc Lacroix > ... >Here are described nearly 150 drugs that are currently used in routine > ... The Torture discussion belongs in talk.politics.misc. This group is reserved for discussions of Science. --bks From sviswanadha from gmail.com Sat May 30 05:29:25 2009 From: sviswanadha from gmail.com (group) Date: Sat May 30 13:29:39 2009 Subject: [Cell-biology] Re: TDGA..where to get it?&In-Reply-To= References: Message-ID: <76fe5777-162c-4af3-a6bd-27b3c2876f3a@z5g2000vba.googlegroups.com> Hey Carole: Hope you are doing good. I guess TGDA is probably the same as methyl palmoxirate. Can be obtained from R.W. Johnson Pharmaceutical research Institute. Regards, Srikant On Apr 29, 8:02?pm, "Carole Sztalryd-Woodle" wrote: > I am also looking for it, did you get any answers? > > Carole Sztalryd > Assistant Professor of Medicine > Division of Endocrinology > HH room 445A > 650 West Redwwod Street > Baltimore MD 21201 > (office) 1-410-706-4047 > (lab) 1-410-706-3505 or 3594 > > Confidentiality Statement: > This email message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. ?Any unauthorized use, disclosure or distribution is prohibited. ?If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message. > > ?Carole Sztalryd-Woodle1.vcf > < 1KViewDownload